Interfaces in Immunomedicine (iIMMUNE) (iIMMUNE_ACS)

Third Party Funds Group - Overall project


Acronym: iIMMUNE_ACS

Start date : 01.05.2022

End date : 30.04.2024

Extension date: 30.04.2027

Website: https://www.dzi.uk-erlangen.de/forschung/iimmune/


Project details

Scientific Abstract

The aim of the iIMMUNE_ACS programme is to train advanced clinician scientists (hereinafter ACS) at Erlangen University Hospital and FAU Erlangen-Nuremberg in modern, patient-centred immunology. Our iIMMUNE_ACS programme (Interfaces in Immunomedicine) – Support for Advanced Clinician Scientists in the Field of Immunomedicine – aims to produce future scientific leaders in academic medicine. It promotes clinical and scientific collaboration at the interfaces of immunolomedicine and contributes to innovative diagnosis, prevention and treatment strategies for infectious, inflammatory, autoimmune, neoplastic and CNS diseases. Immunomedicine has already demonstrated its enormous potential in the treatment of certain diseases and is currently revolutionising medical practice across numerous disciplines. Over the past two decades, the Faculty of Medicine at FAU has demonstrated its excellence in this field. Joint efforts to improve personalised patient care include participation in national and international research consortia and strategic initiatives such as the establishment of the German Centre for Immunotherapy (DZI) and the Centre for Immunotherapy, Biophysics and Digital Medicine (CITABLE). iIMMUNE_ACS recruits outstanding senior specialists working at various interfaces of immunomedicine. The programme offers individual support to help participants become experts in their field and equip them with the skills required of academic leaders. Furthermore, iIMMUNE_ACS will enable the funded project leaders to integrate various aspects of immunomedicine and combine innovative immunolomedicine-based approaches with state-of-the-art analytical and biophysical tools and the possibilities offered by digital medicine. Our programme prepares them for their future roles in immunomedicine as doctors, university lecturers and scientists.

Involved:

Contributing FAU Organisations:

Funding Source